Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells

Cancer Letters

Volumn 277, Issue 2, 2009, Pages 141-148

  Jan, Hsun Jin ^a   Lee, Chin Cheng ^b   Lin, Yu Min ^b   Lai, Jing Huei ^a   Wei, Hen Wei ^c   Lee, Horng Mo ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Glioma; Matrix metalloproteinase; Mitogen activated protein kinase phosphatase 1

Indexed keywords

GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SMALL INTERFERING RNA; TRIPTOLIDE;

ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME RELEASE; GLIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; DUAL SPECIFICITY PHOSPHATASE 1; GLIOMA; HUMANS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 62849099510     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.033     Document Type: Article

References (28)

1. Brandsma D., Stalpers L., Taal W., Sminia P., and van den Bent M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9 (2008) 453-461
2. Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62 (2008) 31-50 discussion 50-52
3. Nakada M., Okada Y., and Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front. Biosci. 8 (2003) e261-269
4. Kargiotis O., Chetty C., Gondi C.S., Tsung A.J., Dinh D.H., Gujrati M., Lakka S.S., Kyritsis A.P., and Rao J.S. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 27 (2008) 4830-4840
5. Koul D., Parthasarathy R., Shen R., Davies M.A., Jasser S.A., Chintala S.K., Rao J.S., Sun Y., Benvenisite E.N., Liu T.J., and Yung W.K. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20 (2001) 6669-6678
6. Hong I.K., Kim Y.M., Jeoung D.I., Kim K.C., and Lee H. Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells. Exp. Mol. Med. 37 (2005) 230-239
7. Huang X., Chen S., Xu L., Liu Y., Deb D.K., Platanias L.C., and Bergan R.C. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65 (2005) 3470-3478
8. Galli A., Svegliati-Baroni G., Ceni E., Milani S., Ridolfi F., Salzano R., Tarocchi M., Grappone C., Pellegrini G., Benedetti A., Surrenti C., and Casini A. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 41 (2005) 1074-1084
9. Mooradian A.D., Chehade J., and Thurman J.E. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat. Endocrinol. 1 (2002) 13-20
10. Kulke M.H., Demetri G.D., Sharpless N.E., Ryan D.P., Shivdasani R., Clark J.S., Spiegelman B.M., Kim H., Mayer R.J., and Fuchs C.S. A phase II study of troglitazone An activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 8 (2002) 395-399
11. Strakova N., Ehrmann J., Dzubak P., Bouchal J., and Kolar Z. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J. Pharmacol. Exp. Ther. 309 (2004) 1239-1247
12. Lea M.A., Sura M., and Desbordes C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res. 24 (2004) 2765-2771
13. Galli A., Ceni E., Crabb D.W., Mello T., Salzano R., Grappone C., Milani S., Surrenti E., Surrenti C., and Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 53 (2004) 1688-1697
14. Abe A., Kiriyama Y., Hirano M., Miura T., Kamiya H., Harashima H., and Tokumitsu Y. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur. J. Pharmacol. 436 (2002) 7-13
15. Chang P.C., Chen T.H., Chang C.J., Hou C.C., Chan P., and Lee H.M. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int. 65 (2004) 1664-1675
16. Keyse S.M., and Emslie E.A. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359 (1992) 644-647
17. Wu G.S. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev. 26 (2007) 579-585
18. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
19. Wang X., and Liu Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell Signal 19 (2007) 1372-1382
20. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27 (2008) 253-261
21. Pan M.R., Chang H.C., and Hung W.C. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal 20 (2008) 1134-1141
22. Lin Y.M., Jan H.J., Lee C.C., Tao H.Y., Shih Y.L., Wei H.W., and Lee H.M. Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur. J. Pharmacol. 593 (2008) 1-9
23. Bai Y.P., Liu Y.H., Chen J., Song T., You Y., Tang Z.Y., Li Y.J., and Zhang G.G. Rosiglitazone attenuates NF-kappaB-dependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem. Biophys. Res. Commun. 360 (2007) 20-26
24. Cimini A., Cristiano L., Colafarina S., Benedetti E., Di Loreto S., Festuccia C., Amicarelli F., Canuto R.A., and Ceru M.P. PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int. J. Cancer 117 (2005) 923-933
25. Akasaki Y., Liu G., Matundan H.H., Ng H., Yuan X., Zeng Z., Black K.L., and Yu J.S. A peroxisome proliferator-activated receptor-gamma agonist troglitazone facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem. 281 (2006) 6165-6174
26. Grommes C., Landreth G.E., Sastre M., Beck M., Feinstein D.L., Jacobs A.H., Schlegel U., and Heneka M.T. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol. Pharmacol. 70 (2006) 1524-1533
27. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., Moses M.A., Kilroy S., Duensing S., Fletcher C., Fletcher J.A., Hlatky L., Hahnfeldt P., Folkman J., and Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110 (2002) 923-932
28. Abaraviciene S.M., Lundquist I., Salehi A., and kinase R.c.p.-i.b.-c.d.b.s.o.M. inducible nitric oxide synthase and caspase-3 activities. Cell. Mol. Life Sci. 65 (2008) 2256-2265